

Monensin Solution (1,000X)

Catalog# / Size 420701 / 1 mL

Regulatory Status RUO

Description Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, *et al.*, 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during *in vitro* cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details

Formulation Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.

Concentration 2.0 mM

Storage & Handling Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.

Application [ICFC - Quality tested](#)

Recommended Usage Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References

(PubMed link indicates BioLegend citation)

1. Smeltz RB. 2007. *J. Immunol.* 178:4786.
2. Fuse S, *et al.* 2007. *J. Immunol.* 178:5227.
3. Durkin ET, *et al.* 2008. *Blood* 10:1182. [PubMed](#)
4. Durkin ET, *et al.* 2008. *Blood* 112:5245. [PubMed](#)
5. Liu XS, *et al.* 2009. *J. Immunol.* 183:51. [PubMed](#)
6. Mattarollo SR, *et al.* 2010. *J. Immunol.* 184:1242. [PubMed](#)
7. Yang M, *et al.* 2010. *J. Immunol.* 184:3321. [PubMed](#)
8. Mattarollo SR, *et al.* 2010. *J. Immunol.* 184:5663. [PubMed](#)
9. Wood MW, *et al.* 2011. *Infect Immun.* 79:708. [PubMed](#)
10. Janune D, *et al.* 2011. *FEBS Lett.* 585:3033. [PubMed](#)
11. Fiorenza S, *et al.* 2012. *J. Immunol.* 189:5622. [PubMed](#)
12. Asgari E, *et al.* 2013. *Blood.* 122:3473. [PubMed](#)
13. Li D, *et al.* 2013. *Clin Immunol.* 149:411. [PubMed](#)
14. Bunse CE, *et al.* 2013. *PLoS One.* 8:77925. [PubMed](#)

Product Citations

1. Mattarollo S, *et al.* 2010. *J Immunol.* 184:1242. [PubMed](#)
2. Li D, *et al.* 2013. *Clin Immunol.* 149:411. [PubMed](#)
3. Pan YG, *et al.* 2022. *Methods Mol Biol.* 2574:31. [PubMed](#)
4. Aguilar-Pineda JA, *et al.* 2021. *iScience.* 24:102993. [PubMed](#)
5. Munk R, *et al.* 2011. *PLoS One.* 6:e18553. [PubMed](#)
6. Qian Y, *et al.* 2021. *Cell Reports.* 36(8):109602. [PubMed](#)
7. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. *PLoS One.* 11:e0167618. [PubMed](#)
8. Asgari E, *et al.* 2013. *Blood.* 122:3473. [PubMed](#)
9. Bailey S, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-01867-9. [PubMed](#)
10. Durkin E, *et al.* 2008. *Blood.* 112:5245. [PubMed](#)
11. Tian M, *et al.* 2022. *J Clin Invest.* 132:. [PubMed](#)
12. Kimura I, *et al.* 2022. *Cell Rep.* 38:110218. [PubMed](#)
13. Gao F, *et al.* 2021. *Front Cell Infect Microbiol.* 10:593805. [PubMed](#)
14. Yang M, *et al.* 2010. *J Immunol.* 184:3321. [PubMed](#)
15. Izumi K, *et al.* 2021. *Immunohorizons.* 5:687. [PubMed](#)
16. Glaubitz J, *et al.* 2022. *Nat Commun.* 13:4502. [PubMed](#)
17. Datta A, *et al.* 2022. *J Fungi (Basel).* 8:. [PubMed](#)
18. Rana A, *et al.* 2020. *Front Immunol.* 11:536. [PubMed](#)
19. Martens A, *et al.* 2020. *Nat Immunol.* 21:381. [PubMed](#)
20. Theeb W, *et al.* 2017. *Infect Immun.* 10.1128/IAI.00475-16. [PubMed](#)

21. Al-Attar A, *et al.* 2016. Data Brief. 8: 536-44. [PubMed](#)
22. Joosten S, *et al.* 2016. PLoS Pathog. 12: 1005687. [PubMed](#)
23. Fiorenza S, *et al.* 2012. J Immunol. 189:5622. [PubMed](#)
24. Geisness AC, *et al.* 2021. Haematologica. Online ahead of print. [PubMed](#)
25. Douthwaite J, *et al.* 2017. J Immunol. 198(1):528-537. [PubMed](#)
26. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. [PubMed](#)
27. Montes de Oca M, *et al.* 2020. PLoS Pathog. 16:e1008994. [PubMed](#)
28. Steinbuck MP, *et al.* 2021. Sci Adv. 7: . [PubMed](#)
29. Acharya A, *et al.* 2020. J Virol. 95:e01657. [PubMed](#)
30. Park HB, *et al.* 2020. Oncoimmunology. 9:1772663. [PubMed](#)
31. Ries M, *et al.* 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. [PubMed](#)
32. Janune D, *et al.* 2011. FEBS Lett. 585:3033. [PubMed](#)
33. Shenoy AT, *et al.* 2021. Nat Commun. 12:5834. [PubMed](#)
34. Imani J, *et al.* 2021. JCI Insight. 6: . [PubMed](#)
35. Elliott PR, *et al.* 2021. Cell Rep. 37:109777. [PubMed](#)
36. Bunting MD, *et al.* 2022. Sci Adv. 8:eabk3327. [PubMed](#)
37. Uddin MN, *et al.* 2022. Brain Behav Immun Health. 26:100563. [PubMed](#)
38. Takushi SE, *et al.* 2020. Hum Gene Ther. 31:626. [PubMed](#)
39. Ren Y, *et al.* 2022. J Immunother Cancer. 10: . [PubMed](#)
40. Orlov M, *et al.* 2017. PLoS One. 10.1371/journal.pone.018296. [PubMed](#)
41. Mittal P, *et al.* 2020. Cancers (Basel). :12. [PubMed](#)
42. Gross C, *et al.* 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. [PubMed](#)
43. Vacaflores A, *et al.* 2016. PLoS One. 11: 0157175. [PubMed](#)
44. Johnson AM, *et al.* 2020. J Immunol. 204:2295. [PubMed](#)
45. Huang RS, *et al.* 2021. Curr Protoc. 1:e246. [PubMed](#)
46. Sendler M, *et al.* 2020. Gastroenterology. 158:253. [PubMed](#)
47. Ngwenyama N, *et al.* 2019. JCI Insight. 4:e125527. [PubMed](#)
48. Chen YF, *et al.* 2019. J Biomed Sci. 26:85. [PubMed](#)
49. Nice T, *et al.* 2016. PLoS One. 12: 1005684. [PubMed](#)
50. Krishnan A, *et al.* 2020. Am J Pathol. 190:1284. [PubMed](#)
51. de Picciotto S, *et al.* 2022. Nat Commun. 13:3866. [PubMed](#)
52. Shafer S, *et al.* 2021. J Allergy Clin Immunol. 148:256. [PubMed](#)
53. Teh MR, *et al.* 2021. Front Immunol. 12:714613. [PubMed](#)
54. Liu X, *et al.* 2009. J Immunol. 183:51:00. [PubMed](#)
55. Gladow N, *et al.* 2020. PLoS One. 15:e0227734. [PubMed](#)
56. Loeuillard E, *et al.* 2020. J Clin Invest. 130:5380. [PubMed](#)
57. Mandour MF, *et al.* 2020. Infect Agent Cancer. 15:30. [PubMed](#)
58. Wood M, *et al.* 2011. Infect Immun. 79:708. [PubMed](#)
59. Ren Y, *et al.* 2015. Biochim Biophys Acta. Available online 14 August 2015. [PubMed](#)
60. Sabag B, *et al.* 2022. Cancers (Basel). 14: . [PubMed](#)
61. FitzPatrick MEB, *et al.* 2021. Cell Rep. 34:108661. [PubMed](#)
62. Dimeloe S, *et al.* 2016. J Immunol. 196: 106 - 114. [PubMed](#)
63. Bunse C, *et al.* 2013. PLoS One. 8:77925. [PubMed](#)
64. Burger ML, *et al.* 2021. Cell. 184:4996. [PubMed](#)
65. Landi A, *et al.* 2017. Vaccine. 10.1016/j.vaccine.2017.10.072. [PubMed](#)
66. Liu X, *et al.* 2020. Ther Adv Med Oncol. 12:1758835920910347. [PubMed](#)
67. Seenappa LM, *et al.* 2022. NPJ Vaccines. 7:128. [PubMed](#)
68. Bonavita E, *et al.* 2020. Immunity. 1215:53. [PubMed](#)
69. Mackroth M, *et al.* 2016. PLoS Pathog. 12:e1005909. [PubMed](#)
70. Spiljar M, *et al.* 2021. Cell Metab. 33:2231. [PubMed](#)
71. Ruland C, *et al.* 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. [PubMed](#)
72. Mattarollo S, *et al.* 2010. J Immunol. 184:5663. [PubMed](#)
73. Krishna B, *et al.* 2016. Sci Rep. 6: 24674. [PubMed](#)
74. Schridde A, *et al.* 2017. Mucosal Immunol. 10.1038/mi.2016.142. [PubMed](#)
75. Kumar S, *et al.* 2021. JCI Insight. 6:e145228. [PubMed](#)
76. Fujiwara Y, *et al.* 2021. Nat Commun. 12:5857. [PubMed](#)
77. Laczko D, *et al.* 2020. Immunity. 53:724. [PubMed](#)
78. Marvin S, *et al.* 2017. J Virol. 10.1128/JVI.01417-16. [PubMed](#)

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 *Detection of Intracellular Cytokines by Flow Cytometry* (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65.
3. Sander B, *et al.* 1993. *J. Immunol. Meth.* 166:201.
4. Prussin C, *et al.* 1995. *J. Immunol. Meth.* 188:117.
5. Jung T, *et al.* 1993. *J. Immunol. Meth.* 159:197.

Gene ID

NA

Related Protocols

[Intracellular Flow Cytometry Staining Protocol](#)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587